Thymoma: A Focus on Current Therapeutic Management  by Girard, Nicolas et al.
STATE OF THE ART: CONCISE REVIEW
Thymoma
A Focus on Current Therapeutic Management
Nicolas Girard, MD,*† Franc¸oise Mornex, MD, PhD,* Paul Van Houtte, MD,‡
Jean-Franc¸ois Cordier, MD,† and Paul van Schil, MD, PhD§
Abstract: Thymomas are rare intrathoracic malignant tumors. Com-
monly used staging system is the Masaoka classification, based on
peroperative and histopathological findings. Surgery is the corner-
stone of the management of thymomas, initially being useful for
precise histopathological diagnosis and staging, and in most cases
ensuring the first step of the therapeutics simultaneously. After
tumor stage, complete resection is the most constant and significant
prognostic factor for progression-free and overall survival. Postop-
erative radiotherapy is recommended in incompletely resected thy-
momas. Completely resected stage II and III tumors may also benefit
from adjuvant radiotherapy to reduce local recurrence rates but
without impact on survival. In primary unresectable thymomas,
multimodal strategy nowadays includes neoadjuvant chemotherapy,
extensive surgery, adjuvant radiotherapy, and in some cases, adju-
vant chemotherapy. The most popular chemotherapy regimens com-
bine cisplatin, adriamycin, etoposide, cyclophophamide, or ifosf-
amide.
The management of thymomas is a paradigm of cooperation
between clinicians, surgeons, and pathologists from establishing the
diagnosis to organizing the therapeutic strategy and evaluating the
prognosis. As a consequence of their rarity, no prospective random-
ized trials are available and collaborative studies are warranted to
evaluate and improve current therapeutic standards, taking into
account recent improvements in techniques, such as robotic surgery,
radiotherapy, and supportive treatments.
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Thymomas are uncommon intrathoracic malignant tumors.As a consequence of their rarity, knowledge regarding
these tumors is mainly based upon case reports or small
retrospective series, most of which were published years ago.
Even if sometimes difficult to interpret, these studies never-
theless provide a good overview of the results of surgical
resection, and the role of radiotherapy and chemotherapy.
Publication bias regarding the inclusion of patients (medical,
surgical or pathologic studies) may hamper the estimation of
the individual weight of each therapeutic option in the mul-
timodal treatment of these tumors.
Thus, the objectives of this chapter are to (1) describe
available therapeutic options for thymomas, (2) review their
indications in adults, and (3) provide a comprehensive anal-
ysis of current treatment recommendations, using standard
grading system.1 As thymic carcinomas and carcinoids are
extremely uncommon, they will not be considered for this
review.
Thymoma: Clinical Staging Considerations
Thymomas are rare malignant epithelial tumors, ac-
counting for less than 0.5% of all cancers. Their main
pathologic characteristics include a wide range of cytologic
patterns within thymic epithelial cells, and the association
with a nontumoral lymphocytic component, whose relative
proportion to neoplastic cells is the basis of the current World
Health Organization (WHO) histopathological classification
(Table 1).2 The thymus gland induces the differentiation of T
lymphocytes, what may provide an explanation for the wide
spectrum of autoimmune manifestations associated with thy-
moma.
Even if the WHO classification has been designed to
assume some prognostic value (Table 1), the most significant
factor for survival is the invasiveness of the tumor.3–15 Sev-
eral staging systems have been described. The Masaoka and,
especially in continental Europe, the French Groupe d’Etude
des Tumeurs Thymiques (GETT) classifications are mostly
used, as they are based on peroperative and histopathological
findings, the latter offering the advantage of being clearly
connected to therapeutic options (Table 2).6,8 Moreover, the
concordance between these 2 classifications is higher than
85%.16 The unauthorized Tumor-Node-Metastasis system
proposed in 1991 has never been formally adopted, even in
recent studies.17
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Cooperation between surgeons and pathologists is man-
datory to establish the accurate staging of thymomas. Indeed,
the pathologic definition of invasive tumors may vary, refer-
ring either to (1) capsular invasion, as proposed in the
original report of Masaoka et al.8, but which is difficult to
assess unless the capsule is completely breached, or (2)
invasion beyond the capsule in the mediastinal fat, corre-
sponding to microscopic invasion, which may also be hard to
distinguish from persistent thymic remnants, especially in
B1–B2 lymphocytes-rich subtypes. Moreover, peroperative
clinical findings of invasiveness, especially tight adherence to
surrounding structures and pleural adhesion, are not corre-
lated with microscopic invasion.4
Overall, invasive thymomas belong to Masaoka stage II
to IV tumors and account for 35 to 45% of cases. Mostly,
invasion consists of direct local and regional spread within
the lung, the pleura, and the pericardium (some patterns
rather considered as “droplet” local spread), thus classified as
stage III, than true hematogenous or lymphogeneous dissem-
ination. Rare droplet lesions may even occur within the
peritoneum, by direct spread through the diaphragmatic ori-
fices. The WHO classification is highly correlated to stage, as
80 to 90% of A to B1 thymomas are stage I-II tumors,
whereas 50 to 60% of B2, and 60 to 80% of B3 and C tumors
are stage III–IV, a unique feature which may explain the
prognostic value of the pathologic classification (Table 1).3,4
General Therapeutic Principles
Surgery
Surgery is the cornerstone of the management of thy-
mic tumors, being most useful for the initial histopathological
diagnosis and staging, and in most cases providing the first-
line therapeutic modality. For resectable anterior mediastinal
tumors compatible with thymoma, immediate surgical resec-
tion is advocated; in this way, the capsule is left intact and
spoiling avoided. In cases of unresectable tumors or suspicion
of lymphoma, fine-needle aspiration or surgical biopsies are
recommended.18
As a standard, the surgical management of thymoma
requires the wide opening of the mediastinum and both
pleural cavities, which is classically achieved by median
sternotomy.7,16 In the surgical literature, at least 10 different
approaches to the thymus have been described and these are
summarized in Table 3.19–22 Unfortunately, there are no
randomized studies showing one technique to be superior
over another. Voluminous tumors for which parenchymal
lung resection is anticipated, may be operated through an
anterior bilateral thoracotomy and transverse sternotomy, a
TABLE 1. The World Health Organization Histopathological Classification of Thymomas1
Type WHO Classification-Pathological Features Invasiveness 10-yr Disease-Free Survival
A Spindle cell and medullary thymoma, lymphocyte-poor area 10–40% 100%
AB Mixed pattern of type A (lymphocyte-poor) and type B (lymphocyte-rich) thymoma 30–40% 100%
B1} {Thymoma resembling the normal thymus 45–50% 85%B2 65–70% 85%
B3 Sub-types B1, B2, and B3 differentiated by an increasing epithelial/lymphocyte ratio and
the emergence of atypia
85–90% 35%
WHO, World Health Organization.
TABLE 2. Correspondence Between the Masaoka and the Groupe d’Etude des Tumeurs Thymiques (GETT) Staging
Classifications.1,5,7 Overall Survival and Survival in Completely Resected Tumors1,3,5,7
Masaoka Staging GETT Classification Complete Resection Overall Survival
Stage Description Stage Description 5-yr 10-yr
I Macroscopically completely
encapsulated
IA Encapsulated tumor, totally resected 95–100% 90–100% 85–95%
IIA Macroscopic invasion into
surrounding fatty tissue,
mediastinal fat, or both
IB Macroscopically encapsulated tumor,
totally resected, peroperative
suspicion of mediastinal adhesion or
potential capsular invasion
85–100% 75–90% 70–85%
IIB Microscopic invasion into the
capsule
II Invasive tumor, totally resected
III Macroscopic invasion in
neighboring organs, such as
pericardium, great vessels, or
lung
IIIA Invasive tumor, sub-totally resected 65–80% 50–70% 25–60%
IIIB Invasive tumor, biopsy
IVA Pleural and pericardial
dissemination
IVA Supraclavicular metastasis or distant
pleural droplets
30–50% 30–40% 0–15%
IVB Lymphogeneous or
haematogeneous metastasis
IVB Distant metastasis
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so-called “clamshell” incision. Regarding the need for a
complete exploration of the thorax to achieve accurate mar-
gins and complete staging, cervicotomy only, as described in
older reports to reduce the risk of anesthesia in patients with
associated myasthenia gravis, is no longer indicated. Simi-
larly, videothoracoscopy is contraindicated in large tumors to
avoid any peroperative spread of tumor cells within the
pleura. However, with the advent of robotic techniques pro-
viding superb three-dimensional visualization and highly
flexible robotic arms, thymomas up to 4 cm may be resected
safely. In a recent prospective single-center series of 106
consecutive robotic-assisted thymectomies, there was no
mortality, and morbidity was only 2%.23 In a retrospective
comparative analysis, operative time was higher with the
robotic approach, but hospital stay was shorter and neuro-
logic outcome seemed to be better.24
The first step of the operation consists of a careful
examination of the mediastinum and pleural cavities, fol-
lowed by evaluation of macroscopic capsular invasion, peri-
tumoral and pleural adhesions, and involvement of surround-
ing tissues. Careful exploration of the mediastinal pleura,
especially in the costodiaphragmatic sinuses, may detect
droplet metastases. These findings, together with the subse-
quent pathologic examination of the surgical specimen, con-
stitute the basis of the staging system of thymomas, according
to the Masaoka, and furthermore the GETT classifications
(Table 1).6,8 Areas of uncertain margins are marked with clips
to allow precise delivery of postoperative radiotherapy.
Radiotherapy
Radiotherapy has mainly been reported as an exclusive
or adjuvant treatment for thymomas. Evolving trends for
locally advanced tumors include multimodal chemoradiation
strategies. Current modalities of radiotherapy for thymoma
include (1) the use of multifield arrangement conformal
radiotherapy and three-dimensional treatment planning; (2) a
clinical target volume including the whole thymic space, the
tumor and its extensions, and the anterior, superior, and
middle mediastinum (with reduction of fields after a total
dose of 50–55 Gy). Prophylactic supraclavicular nodes irra-
diation is no longer recommended, as isolated recurrences in
this area are exceptional.12,13 Some reports indicate the fea-
sibility and efficacy of delivering a 15 Gy prophylactic
hemithoracic irradiation, with a reduction of pleural recur-
rences rates from 100% to 60%, without effect on overall
survival25; (3) a total dose ranging from 40 to 60 Gy,
including a boost on the tumor bed in incompletely or
nonresected lesions, as mentioned, surgical clips may be then
useful to plan the gross tumor volume-, with a standard-
fractionation scheme consisting in daily doses from 1.8 to 2
Gy over a 4 to 6 weeks-period.
Although thymomas have been recognized as highly
radiosensitive for years, the benefit of dose escalation on
local control has not clearly been established. Arriagada et
al.26 reported similar local control rates with total doses
inferior to 48 Gy or superior to 60 Gy. However, in the
French series reported by Mornex et al.,13 local recurrence
rate in stage III–IV resected tumors was as high as 80% after
adjuvant radiotherapy delivered to median doses of 45 to 50
Gy. This led most investigators to increase radiation doses to
60 to 65 Gy, which was made possible with the availability of
conformal radiation planning systems.
The toxicity of radiotherapy for thymic tumors depends
on the amount of normal tissues included within the radiation
portal, and mainly consists of radiation-induced acute peri-
carditis and pneumonitis, and late coronary disease and lung
fibrosis.13 No data are yet available regarding the use of new
radiation delivery techniques, such as intensity modulated,
respiratory gating, and proton-beam radiotherapy, to reduce
these late effects.
The interpretation of reported data regarding radiother-
apy as a single modality for thymomas is difficult, as only
small series have been published, most of which included
patients with various tumor stages, heterogeneous perfor-
mance status, and different total radiation doses and tech-
niques. Overall, local control rates following exclusive radio-
therapy in nonresectable tumors might not be higher than 45
to 50%.27,28
The role of adjuvant radiotherapy in thymic tumors has
been debated for years, and has to be discussed both regard-
ing the tumor stage and the completeness of the surgical
resection. In reported series of thymomas, radiotherapy was
also delivered in a neoadjuvant setting to 10–20% of
patients, mostly bearing stage IV primary unresectable
tumors, in association with chemotherapy.29 The precise
effect of neoadjuvant radiotherapy is difficult to determine
in these heavily treated patients. The feasibility and effi-
cacy of preoperative radiotherapy to a total dose of 18 Gy
has also been reported in patients with great vessel inva-
sion or mediastinal compression, to achieve subsequent
complete resection.30
Chemotherapy
Evidence-based data regarding the role of chemotherapy
for thymomas are scarce, mainly due to the small populations
studied. The chemosensitivity of thymoma was established in
many small studies reporting the efficacy of single-agent che-
motherapy regimens in nonresectable tumors (Table 4). The
highest responses rates were observed in controlled studies
TABLE 3. Surgical Approaches to the Thymus
1. Transcervical only
2. Transsternal
Full median sternotomy
Partial sternotomy (manubriotomy)
3. VATS (video-assisted thoracic surgery)
Unilateral (right or left)
Bilateral (right  left  subxiphoid)
Robotic techniques (right or left)
4. Combined
Transcervical  sternal retractor
Transcervical  partial sternotomy
VATS  cervical incision
Bilateral anterior thoracotomy  transverse sternotomy (clam shell)
VATS, video-assisted thoracic surgery.
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with cisplatin and ifosfamide.31,32 Noncisplatin containing
regimens have been abandoned for many years. Current
standard regimens include the following: cisplatin and eto-
poside33; cisplatin, adriamycin, cyclophosphamide (PAC)34;
adriamycin, cisplatin, vincristine, cyclophosphamide
(ADOC)35; and etoposide, ifosfamide, cisplatin (VIP)36 (Ta-
ble 4). However, these have never been compared with
single-agent regimens in a randomized setting. Response
rates range between 32 and 92%, including 10 to 43% of
complete responses (Table 4). In the 10-year observational
study reported by Giaccone et al.,37 the PAC and the VIP
regimens were the most used in an exclusive setting, and
overall response rate was 32%. The VIP regimen, even if
showing slightly lower responses rates, is significantly less
toxic than the PAC regimen.
Nonchemotherapeutic systemic treatments have also
been used in nonresectable thymoma. The association of
octreotide and prednisone, based on the evidence of growth
hormone secretion by thymic epithelial cells, has been re-
ported as an effective treatment in thymomas which show up
positive on octreoscan, achieving an objective response rate
as high as 30%.38 Targeted therapies have been disappoint-
ing, despite the overexpression of epidermal growth factor
and c-Kit39,40: reported response rates to gefitinib and ima-
tinib are as low as 1 to 4%, what may be explained by the
exceptional presence of activating mutations of the corre-
sponding targeted genes in these tumors.37,39–42
Finally, in all these studies, the evaluation of response
to chemotherapy rarely takes into account (1) the short-term
effect of associated corticoids on the lymphocytic cells,
which may be important in AB and B lymphocyte-rich
subtypes, without efficiency on the epithelial tumoral com-
ponent, and (2) the possible rebound thymic hyperplasia after
chemotherapy.43
Current Therapeutic Recommendations in
Thymic Tumors
Masaoka-Stage I Thymomas
The treatment of Masaoka stage I thymoma consists of
upfront surgery, although its role has never been proven in a
randomized study. Peroperatively, resectability is carefully
evaluated. Extended thymectomy is indicated in every case
including the thymic gland and complete resection of all
perithymic fat.15 Capsular invasion may be subtle and not
visible by the surgeon, so the tumor should not be shelled out
but rather resected with all surrounding tissues. In the ab-
sence of capsular invasion at pathologic examination (stage
IA tumors in the GETT classification), no adjuvant treatment
is recommended.44 However, the major challenge is to ensure
the absence of microscopic invasion, which may require a
clarification of the pathologic definition of capsular invasion.
Completely resected stage I thymomas carry a 0.9%-overall
recurrence risk and a 5-year survival of 100% after surgery as
single treatment modality.44 Adjuvant radiotherapy in these
cases will not provide any additional survival benefit.45,46 In
all cases, mandatory follow-up should be longer than 10
years, as late recurrences are described up to 15 years after
initial resection.7
In medically inoperable patients, exclusive radiother-
apy may improve local control, although overall survival may
not be influenced.
Recommendation: for stage I thymoma, surgery is rec-
ommended with the aim to obtain a microscopically complete
resection (level of evidence 1C).
Masaoka–Stage II–III Resectable Thymomas
The treatment of Masaoka stage II–III resectable
thymomas also consists of upfront surgery. After tumor
TABLE 4. Prospectively Evaluated Chemotherapy Regimens in Thymic Tumors
Regimen Drugs Doses
Response Rate
ReferenceOverall Complete
Single agent
Cisplatin 50 mg/m²/3 wk 10–62% 10% 31
Ifosfamide 1.5 g/m²  5 d/3 wk 46–54% 38% 32
Multiple agents
PE Cisplatin 60 mg/m²/3 wk 56–60% 31% 33
Etoposide 120 mg/m²  3/3 wk
PAC Cisplatin 50 mg/m²/3 wk 51% 10% 34
Adriamycin 50 mg/m²/3 wk
Cyclophosphamide 500 mg/m²/3 wk
ADOC Adriamycin 40 mg/m²/3 wk 85–92% 40–43% 35
Cisplatin 50 mg/m²/3 wk
Vincristine 700 mg/m²/3 wk
Cyclophosphamide 0.6 mg/m²/3 wk
VIP Etoposide 75 mg/m²  4 d/3 wk 32% 0% 36
Ifosfamide 1.2 g/m²  4 d/3 wk
Cisplatin 20 mg/m²  4 d/3 wk
PE, cisplatin and etoposide; PAC, cisplatin, adriamycin, cyclophosphamide; ADOC, adriamycin, cisplatin, vincristine, cyclophosphamide; VIP,
etoposide, ifosfamide, cisplatin.
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stage, complete resection which is obtained in 50 to 70%
of cases, is the most constant and significant prognostic
factor for progression-free and overall survival in thymo-
mas (Table 1).5,7,9 –12,14–16 As most thymic lesions are initially
operated, some European authors have criticized the Masaoka
staging system, which, contrary to the GETT classification, does
not take into account the completion of upfront surgical resec-
tion. The GETT classification may thus better reflect the aggres-
siveness of thymomas: for example, Masaoka-stage III tumors
undergoing complete resection may achieve similar survival
rates to stage I tumors, with a 5-year progression-free survival up
to 95%.12 These tumors are thus “up-classified” as stage II in the
GETT system.
In completely resected Masaoka stage II and III (GETT
stage II) thymomas, adjuvant radiotherapy reduces local re-
currence rates from 28–36% to 0–5%, and from 53% to 28%,
respectively.13,45,47 This benefit may exist especially in tu-
mors showing capsular invasion (Masaoka stage IIB and III).
In incompletely resected tumors, Curran et al.47 reported that
postoperative radiotherapy also increased mediastinal recur-
rence-free survival from 0 to 79%. These results were better
than the 47% recurrence-free survival of patients having
received complete resection without adjuvant radiotherapy,
suggesting that postoperative radiotherapy could even catch
up an incomplete resection.47 However, postoperative radia-
tion has never been reported to increase overall local control
rate and survival.10,16,45 Overall, if postoperative radiation to
total doses above 50 to 55 Gy achieves relapse rates within
the radiation field as low as 15 to 20%, radiotherapy fails to
control recurrent pleural dissemination, what may reflect the
normal tumor dissemination pattern before or during sur-
gery.10,12 Some authors reported the use of hemithoracic
prophylactic radiation, while others suggested that delivering
radiation in a neoadjuvant setting may decrease the rate of
pleural recurrences.10,48
In case of incomplete resection (GETT stage IIIA
tumors), postoperative radiotherapy is systematically recom-
mended to a total dose of 60 to 65 Gy including the boost on
areas of macroscopic invasion (marked with surgical clips).
Recommendation: for resectable Masaoka stage II–III
thymomas, surgery is recommended (level of evidence 1C).
The role of postoperative radiotherapy remains controversial
but is clearly recommended for incompletely resected tumors
(level of evidence 2C).
Masaoka-Stage III–IVA Marginally Resectable
Thymomas
Surgical procedures for invasive stage III–IVA thymic
tumors include some specific crucial issues: (1) extensive en
bloc resection of the tumor, cervical and mediastinal fat, and
all invaded local structures. If no fat plane exists between the
tumor and the pericardium, frozen tissue examination with
clear indication of suspicious margins is mandatory to ensure
complete resection; otherwise, en bloc resection of the un-
derlying pericardium may be necessary. Major vascular re-
sections have been reported to be feasible, including the
removal and prosthetic reconstruction of the superior vena
cava, innominate veins, aortic arch, anterior wall of the
pulmonary artery, and even the cardiac right cavities49–51; (2)
the maximal preservation of phrenic nerves, especially in
patients with associated myasthenia gravis to avoid respira-
tory insufficiency. Unilateral resection of the involved
phrenic nerve is optional (5% of cases), and may be balanced
by the positioning of surgical clips to plan a subsequent
adjuvant radiation boost. However, phrenic nerve resection
may be inevitable, especially in cases requiring pericardial
resection7; (3) the possible need for lung parenchymal resec-
tion, reported in almost 10% of cases, which consists in most
cases of limited resection rather than traditional lobectomy or
pneumonectomy.14 However, pleuropneumonectomy has
been successfully performed in selected patients with stage
IVA lesions52; and finally, (4) the peroperative control of
doubtful resection margins using fresh-frozen tissue exami-
nations, a meticulous ink-labeling of surgical specimens, and
the application of surgical clips to guide subsequent postop-
erative radiotherapy. In recent series, overall reported mor-
bidity and mortality rates range from 10% to 15%, and 1% to
3%, respectively.5,7 In case of resectable pleural droplets
metastases, surgical resection is controversial but may be
performed, possibly after induction chemotherapy.53–55
The role for incomplete (“debulking”) surgery in pa-
tients with stage III–IVA thymomas has been debated for
many years, mainly following small, retrospective and heter-
ogeneous series which showed survival rates of only 5 to
10%. Improvement in surgical techniques allows more exten-
sive resection, in particular as part of multimodality treat-
ment. Furthermore, an eventual incomplete resection signif-
icantly reduces local recurrences in comparison to a simple
tumor biopsy: in the French series of Mornex et al. local
control rates were 46% versus 16%, respectively.11,13
Adjuvant chemotherapy has been reported to favorably
influence survival in patients with Masaoka stage III–IV
thymomas.13,16 However, chemotherapy has never been di-
rectly compared with radiotherapy in an adjuvant setting, but
has mostly been applied sequentially, before or after radio-
therapy. Main regimens were cisplatin-based, including cis-
platin, epirubicine, etoposide (CEE) and PAC.13,56 In incom-
pletely resected tumors, response rates were higher when
chemotherapy was administered before radiotherapy, than
after radiotherapy (60–62% versus 40–55%, respectively).
In sequential association with chemotherapy, radiotherapy
was delivered to total doses ranging from 30 to 70 Gy.
Recommendation: for Masaoka-stage III–IVA margin-
ally resectable thymomas, surgery and postoperative radio-
therapy are recommended (level of evidence 1C). Periopera-
tive chemotherapy may be delivered in cases of incomplete
resection (level of evidence 2C).
Masaoka-Stage III–IVA Initially Unresectable
Thymomas
Chemotherapy is the initial treatment of Masaoka-stage
III–IVA unresectable thymomas. The main objective is to
reduce the tumor volume either to allow subsequent surgery
with higher chances of achieving negative margins, or to
deliver radiotherapy sparing more nontumoral tissue. In a
neoadjuvant setting, most protocols used the VIP regimen.34
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Response rates of 50% are higher than in an exclusive
setting.37 Other regimens used in a neoadjuvant setting are the
CEE and the PAC-methylprednisolone associations, with
response rates up to 92%.57–59
Several recent, but only small series including no more
than 7 to 22 patients, reported the feasibility of extensive
resection after response to neoadjuvant chemotherapy with
CEE, ADOC, or PAC regimens and followed by postopera-
tive radiotherapy to total doses from 30 to 60 Gy, and by
adjuvant chemotherapy in some cases.54–56,58–62 The high
response rates to neoadjuvant chemotherapy, ranging from 77
to 100%, associated with survival rates ranging from 77 to
95%, may question, when compared with the results of
similar strategy in locally advanced non-small cell lung
cancer. However, local control was achieved in more than
80% of cases in these series.
For thymomas definitely judged to be unresectable,
chemoradiation is administered. Chemotherapy and radio-
therapy in this setting have always been administered
sequentially to avoid the accumulation of treatment toxic-
ities, especially the high risk of radiosensitization with
anthracyclins. Exclusive chemoradiation combining PAC
chemotherapy with standard radiation to a total dose of 54
Gy provided an overall response rate of 70%, and a 5-year
survival of 53%, comparing favorably with the results of
incomplete resection.53
Recommendation: for Masaoka-stage III–IVA initially
unresectable thymomas, multimodal therapy includes upfront
chemotherapy, followed by surgery or radiotherapy, depend-
ing on whether sufficient downstaging is achieved (level of
evidence 2C).
Masaoka-Stage IVB Thymomas
Chemotherapy only is the treatment of choice for stage
IVB thymomas; the PAC and ADOC chemotherapy regimens
may be the most efficient to achieve significant response
rates.37 Subsequent surgery of residual masses and radiother-
apy may be feasible in case of major response to first-line
treatment.53–55
Recommendation: for Masaoka-stage IVB thymomas,
chemotherapy is recommended (level of evidence 1C).
Treatment of Associated Auto-Immune
Manifestations
Associated parathymic manifestations occur in associ-
ation with thymoma in 50 to 70% of cases. The most frequent
parathymic disease is myasthenia gravis, present in 30 to 50%
of cases.63 Identified in old series as a negative prognostic
factor increasing perioperative mortality rates, myasthenia
gravis is presently regarded as a favorable factor influencing
outcome, as it may lead to an earlier disclosure of the tumor.
In 10 to 15% of cases myasthenia gravis precedes the diag-
nosis of thymoma and with current anesthesiologic tech-
niques, the risk of thymectomy has been reduced.63,64
Thymectomy, but also chemoradiation, has been reported to
improve symptoms of myasthenia gravis in 50 to 60% of
cases, with achievement of complete remission in 8 to 30% of
cases.63–65 Recurrence of myasthenia may rarely herald re-
currence of the tumor, but may also be associated with any
other transient medical stress.
Although more than 25 additional parathymic manifes-
tations have been described, few data exist regarding their
evolution after thymectomy: only hypogammaglobulinemia
(10% of thymomas), pure red cell aplasia (5–10% of thymo-
mas), and stiff-person syndrome have been reported to im-
prove with the treatment of the thymic tumor.66,67 Especially,
pure red cell aplasia, rather than hypogammaglobulinemia,
may hamper the completion of the therapeutic strategy. This
especially refers to chemotherapy due to increased hemato-
logical toxicity.
Local and Locoregional Recurrences of Thymoma
Late recurrences occurring more than 5 or 10 years
after resection are not uncommon in thymoma. If local
control mainly depends on the completeness of initial sur-
gery, pleural “droplets” recurrences are rather related to local
spread than to hematogenous metastases. In cases of recurrent
thymoma, surgery, when feasible, remains then the major
therapeutic option.68 Complete reresection, obtained in as
many as 68% of local recurrences,14 obtains a similar out-
come than for those patients without tumor recurrence after
initial resection, with 5-year survival rates ranging from 65%
to 80%.14,50,69 Adjuvant radiation is also feasible.28,69
In nonresectable local recurrences, exclusive radiother-
apy has been reported as an efficient treatment, especially on
pleural recurrences, even if irradiation had previously been
delivered. High response rates with 5-year survival rates as
high as 80% were obtained in small retrospective series.28
Future Directions
The management of thymic tumors is a paradigm of
cooperation between clinicians, surgeons, and pathologists
from establishing the diagnosis to organizing the therapeutic
strategy and evaluating the prognosis. As a consequence of
their rarity, collaborative studies are warranted to evaluate
and improve current therapeutic standards, taking into ac-
count recent improvements in techniques, such as robotic
surgery, radiotherapy, and supportive treatment. Furthermore,
along with the large variety of questions relative to the
therapeutic strategy, thymic tumors represent a model of
therapeutic implementation and achievement in oncology,
showing how the advent of new results induces new ques-
tions, as well as diversifies further clinical research direc-
tions.
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